Table S4.
Combined effect of baseline DBiL concentrations (T1–T2 vs T3) and cigarette smoking (never, ever) on primary and secondary outcomes
| Combined groups
|
Events/N (%) | OR (95% CI)
|
P for interaction | ||
|---|---|---|---|---|---|
| Smoking status | DBiL, μmol/L | Unadjusted | Adjusteda | ||
| Progression of CKD | 0.040 | ||||
| Never | T1–T2 | 160/6454 (2.5) | Ref (1.00) | Ref (1.00) | |
| T3 | 34/2518 (1.4) | 0.54 (0.37–0.78) | 0.54 (0.37–0.80) | ||
| Ever | T1–T2 | 54/1961 (2.8) | Ref | Ref | |
| T3 | 46/1696 (2.7) | 0.98 (0.66–1.47) | 1.00 (0.64–1.55) | ||
| Rapid decline in eGFR | 0.385 | ||||
| Never | T1–T2 | 437/6453 (6.8) | Ref (1.00) | Ref (1.00) | |
| T3 | 122/2518 (4.8) | 0.70 (0.57–0.86) | 0.76 (0.61–0.94) | ||
| Ever | T1–T2 | 138/1961 (7.0) | Ref (1.00) | Ref (1.00) | |
| T3 | 105/1696 (6.2) | 0.87 (0.67–1.13) | 0.89 (0.67–1.17) | ||
| Decline in eGFR, % per year | 0.279 | ||||
| Never | T1–T2 | 1.45 (3.38)b | Ref (0.00) | Ref (0.00) | |
| T3 | 1.10 (3.20)b | −0.35 (−0.50, −0.20)c | −0.34 (−0.50, −0.19)c | ||
| Ever | T1–T2 | 1.50 (3.54)b | Ref (0.00) | Ref (0.00) | |
| T3 | 1.27 (3.43)b | −0.23 (−0.46, 0.00)c | −0.19 (−0.42, 0.03)c | ||
Notes:
a
Adjusted for age, sex, treatment group, systolic blood pressure, body mass index, alcohol intake, eGFR, proteinuria, serum glucose, total cholesterol, alanine aminotransferase, aspartate transaminase at baseline, and time-averaged systolic blood pressure during treatment.
b
Mean (SD).
c
Values are regression coefficients (95% CI).
Abbreviations: DBiL, direct bilirubin; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; OR, odds ratio; 95% CI, 95% confidence interval; Ref, reference; T1, tertile 1; T2, tertile 2; T3, tertile 3.